博瑞医药(688166) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥121,732,693.55, representing a 90.89% increase year-on-year[18]. - Operating income for the first nine months was ¥510,460,593.41, up 62.86% from the same period last year[18]. - Basic earnings per share increased to ¥0.30, a rise of 76.47% compared to the previous year[20]. - The company reported a net profit of ¥276,666,147.98, up from ¥188,553,454.43, indicating a growth of approximately 46.6%[45]. - Total operating revenue for Q3 2020 reached ¥207,153,467.78, a 100.5% increase from ¥103,151,713.44 in Q3 2019[55]. - Net profit for Q3 2020 was ¥48,010,101.65, compared to ¥22,416,532.06 in Q3 2019, representing a 113.5% increase[58]. - The company reported a total profit of ¥58,762,806.31 for Q3 2020, compared to ¥26,804,375.35 in Q3 2019, indicating a 118.5% increase[58]. - Total comprehensive income for the first three quarters of 2020 was ¥80,516,988.68, compared to ¥59,982,303.81 in the same period of 2019, indicating a growth of 34.3%[65]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,666,553,338.58, an increase of 17.26% compared to the end of the previous year[18]. - Total assets increased to ¥1,666,553,338.58, up from ¥1,421,296,902.39, representing a growth of approximately 17.3% year-over-year[43]. - Non-current assets totaled ¥607,208,517.98, compared to ¥359,251,049.87, indicating a significant increase of about 69.1%[43]. - Current liabilities rose to ¥255,924,512.48 from ¥108,210,883.50, reflecting an increase of approximately 136.5%[45]. - Total liabilities amounted to ¥277,124,512.48, up from ¥108,210,883.50, marking an increase of approximately 156.1%[45]. - Total liabilities increased to ¥297,366,060.82 in Q3 2020 from ¥152,675,786.14 in the same period last year, marking a 94.5% rise[55]. - Total assets reached ¥1,659,602,703.70 in Q3 2020, up from ¥1,470,963,482.82 in Q3 2019, representing a growth of 12.8%[55]. Cash Flow - The net cash flow from operating activities for the first nine months was ¥88,988,249.62, a significant increase of 1,260.87% compared to the previous year[18]. - The net cash flow from operating activities was RMB 88,988,249.62, reflecting a 1,260.87% increase due to significant growth in operating revenue[34]. - Cash flow from operating activities for the first three quarters of 2020 was ¥597,715,021.64, significantly higher than ¥356,098,805.22 in the same period of 2019, marking a 67.8% increase[69]. - The net cash flow from operating activities for the first three quarters of 2020 was CNY 28,341,070.27, compared to a net outflow of CNY 50,121,262.41 in the same period of 2019, indicating a turnaround[75]. Shareholder Information - The total number of shareholders at the end of the reporting period was 5,510[22]. - The largest shareholder, Yuan Jiandong, holds 27.69% of the shares, totaling 113,535,123 shares[22]. Research and Development - R&D investment accounted for 18.39% of operating income, down 8.69 percentage points from the previous year[20]. - Research and development expenses for Q3 2020 amounted to ¥30,735,673.97, slightly up from ¥29,332,084.56 in Q3 2019[55]. - Research and development expenses for Q3 2020 totaled ¥24,852,708.46, an increase of 43.5% from ¥17,281,931.57 in Q3 2019[62]. Tax and Income - The company reported a 203.12% increase in income tax expenses to RMB 22,795,566.58, driven by a rise in pre-tax profit[31]. - The tax expense for Q3 2020 was ¥10,752,704.66, compared to ¥4,387,843.29 in Q3 2019, which is a 144.0% increase[58].